Evaluation of Serum Levels of Anti-Helicobacter pylori IgG and IgA by ELISA Method in Patients with Gastric Ulcer in Chalous, Iran
,
Abstract
Background: Considering the role of Helicobacter pylori in various diseases such as chronic gastritis, gastric ulcer and malignancies, this study was performed to evaluate the level of anti-Helicobacter pylori antibodies in the serum of the population of Chalous and then its relationship with demographic characteristics.
Methods: A descriptive study was conducted in the department of Microbiology in a tertiary care teaching hospital during December 2019 to May 2021. All hospitalized patients with diarrhea, who had a history of exposure to antibiotic drugs and all patients with IBD were included in the study. Stool samples were collected from all patients with diarrhea who have been on antibiotic or anticancer drug during last 6weeks or previously diagnosed case. Patient’s demographic features and clinical details were collected from medical records.
Results: About 78% of people had IgA positive titer and about 48% had IgG positive titer. Serum IgA level in patients with bloating (P = 0.005) and in patients with nausea (P = 0.016) was statistically significant. Also, in patients studied there was a significant relationship between bloating (p = > 0.001), nausea (0.013) was seen with a serum IgG level .
Conclusion: Due to the high percentage of positive titers of anti-Helicobacter pylori antibodies, especially IgA in the sample population, it seems that the follow-up of positive serological titers will help to prevent and control the prevalence of Helicobacter pylori infection.
2. Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. The Journal of clinical investigation 2004; 113(3):321-33.
3. Logan RP, Walker MM. ABC of the upper gastrointestinal tract: Epidemiology and diagnosis of Helicobacter pylori infection. BMJ 2001; 323:920-8.
4. Martínez LE, O’Brien VP, Leverich CK, et al. Nonhelical Helicobacter pylori mutants show altered gland colonization and elicit less gastric pathology than helical bacteria during chronic infection. Infect Immun 2019; 87(7):1-15.
5. Pajares J, Gisbert J. Helicobacter pylori: its discovery and relevance for medicine. Revista Espanola de Enfermedades Digestivas 2006; 98(10):770-8.
6. O'Connor A, Furuta T, Gisbert J, et al. Review – treatment of Helicobacter pylori infection 2020. Helicobacter 2020; 25:e12743.
7. Kao CY, Sheu BS, Wu JJ. Helicobacter pylori infection: an overview of bacterial virulence factors and pathogenesis. Biomedical Journal 2016; 39(2):14-23.
8. Choi IJ, Kim CG, Lee JY, et al. Family history of gastric cancer and Helicobacter pylori treatment. N Engl JMed. 2020; 382(5):427-36.
9. Bair MJ, Chuang SL, Lei WY, et al. Planning mass eradication of Helicobacter pylori infection for indigenous Taiwanese peoples to reduce gastric cancer. J Gastroenterology Hepatic 2020; 35:609-16.
10. Choi IJ, Kim CG, Lee JY, et al. Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med 2020; 382:427-36.
11. Hedayati MA, Khani D. Relationship of social risk factors and Helicobacter pylori infection with pathological characteristics of Gastric carcinoma. Iran J Med Microbiol 2020; 20(14):1.
12. Godbole G, Mégraud F, Bessède E. Review: Diagnosis of Helicobacter pylori infection. Helicobacter 2020; 25(1):e12735.
13. Buzás GM. Benign and malignant gastroduodenal diseases associated with Helicobacter pylori: A narrative review and personal remarks in 2018. Minerva Gastroenterology Dettol 2018; 64:280-90.
14. Abdi M, Hakemi-Vala M, Naji T, Nejadeh A, Tajik A. Seroepidemiology of the Helicobacter pylori infection among people of Pishva city of Varamin. Iran J Med Microbiol 2014; 8(4):20-7.
15. Rugge M, Meggio A, Pravadelli C, et al. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut 2019; 68:11-17.
16. Jekarl DW, Choi H, Kim JY, et al. Evaluating diagnostic tests for Helicobacter pylori infection without a reference standard: use of latent class analysis. Ann Lab Med 2020; 40(1):68-72.
17. Merse M, Veceric-Haler Z. The role of IgA in the patho-genesis of IgA nephropathy. Int J Mol Sci 2019; 20(24):266-73.
18. Liu XZ, Zhang YM, Ji NY, et al. Helicobacter pylori infection is associated with elevated galactose-deficient IgA1 in IgA nephropathy. Renal Failure 2020;42(1):539-46.
19. Sadeghifard N, Seidnazari T, Ghafourian S. survey in iran of clarithromycin resistance in Helicobacter pylori isolates by PCR-RFLP. The Southeast Asian journal of tropical medicine and public health 2013; 44(1):45-52.
20. Babamahmoodi F, Âjemi AG, kalhor M, et al;. A sero epidemiological study of Helicobacter pylori infection in Sari in 2001-2002. J Mazandaran Univ Med Sci 2004; 14:39-50.
21. Choopani F, Ghaemi E, Azadfar S, et al. Epidemiology of Helicobacter pylori infection among Iranian children. Arab J Gastroenterol 2013; 14:169-72.
22. Owrang M, Tahmasbpour Marzony E, Imani S, et al. Helicobacter pylori in Iran: A systematic review on the antibiotic resistance Journal of Fasa University of Medical Sciences 2014; 41(1):23-32.
23. Gholizadeh L, Azarnuoshan F , Afrasiabifar A, Mohamad hoseini S. Seroprevalence of Helicobacter Pylori and its Related Factors Among the Students of Islamic Azad University of Gachsaran. Armaghane Danesh 2014; 17(2): 164-173.
24. Sadeghi RH, Monajemzadeh M, Mamishi S. High frequency of metronidazole and clarithromycin-resistant Helicobacter pylori in formalin-fixed, paraffin-embedded gastric biopsies. Br J Biomed Sci 2020; 75:61-5.
25. Shams S, Vesali Jamshid Z, Shahbazi T, et al. Comparison of Serum IgG and IgA Levels against Helicobacter Pylori in patients with gastrointestinal symptoms. Infec Epidemiol Microbiol 2018; 4(3):105-8.
26. Kumar S, Kumar A, Kumar DV. Direct detection and analysis of vacA genotypes and cagA gene of Helicobacter pylori from gastric biopsies by a novel multiplex polymerase reaction assay. J Diagno Microbiol Infect Dis 2008; 62(4):366-73.
27. Sepulveda AR. Helicobacter, inflammation, and gastric cancer. Curr Pathobiol Rep 2013; 1(1):9-18.
28. Hohenberger P, Gretschel S. Gastric cancer Lancet 2003; 362(9380):305-15.
29. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5):277-300.
30. Jafarzadeh A, Mirzaee V, Ahmad-Beygi H, et al. Association of the CagA status of Helicobacter pylori and serum levels of interleukin (IL)-17 and IL23 in duodenal ulcer patients. J Dig Dis 2009; 10(2):107-12.
31. Talebkhan Y, Mohammadi M, Mohagheghi MA, et al. cagA gene and protein status among Iranian Helicobacter pylori strains. Dig Dis Sci 2008; 4(3):925-32.
| Files | ||
| Issue | Vol 12 No 1 (2024) | |
| Section | Original Articles | |
| DOI | https://doi.org/10.18502/jmb.v12i1.15015 | |
| Keywords | ||
| ELISA Gastric Ulcer Helicobacter pylori IgA IgG. | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
